Abstract 2400P
Background
ERBB2 overexpression is an oncogenic driver in many solid tumors, including UBC. Activating mutations (mut) in ERBB2 gene were shown to play an oncogenic role relatively like ERBB2 amplification (amp). We describe and compare the frequency and nature of GA of ERBB2-altered (mut, amp) and ERBB2 wildtype (wt) UBC.
Methods
Using a hybrid capture based comprehensive profiling (CGP) assay, 9,518 UBC cases were evaluated for all classes of GA, tumor mutational burden (TMB), microsatellite instability (MSI), genomic loss of heterozygosity (gLOH), and genomic mutational signature. PD-L1 expression was measured by IHC (Dako 22C3). Statistical comparisons were performed using Fisher’s exact tests.
Results
602 (6.3%) UBC featured ERBB2 extra-cellular domain (ECD) short variant (SV) GA (ECDmut), 253 (2.7%) UBC featured ERBB2 kinase domain (KD) SV GA (KDmut); 866 (9.1%) had ERBB2 amp; 7,797 (81.9%) UBC were ERBB2wt. The GA/tumor was higher in all ERBB2 GA groups vs ERBB2wt. European genetic ancestry of ECDmut+ was higher than ERBB2wt (p=.02). CDKN2A/MTAP loss were more frequent in ERBB2wt vs ECDmut and amp only (both p<.0001). ERBB3 GA was more frequent in ECDmut and KDmut than ERBB2wt (both p<.0001). TERT GA were more frequent in ECDmut, KDmut and amp vs ERBB2wt (all p<.0001). TOP2A amp and TP53 SV GA were significantly higher in ERBB2 amp vs ERBB2wt, ECDmut and KDmut (p<.0001). Mean TMB levels were significantly higher in ECDmut, KDmut and amp than in ERBB2 wt (all comparisons p<.0001). APOBEC signature was more frequent in ECDmut, KDmut and amp vs ERBB2wt (p<.0001). No significant differences in PD-L1 status, MSI-high or gLOH between altered & wt subgroups. The table summarizes key findings. Table: 2400P
ERBB2 (n) | wt (7797) | ECDmut (602) | p | wt (7797) | KDmut (253) | p | wt (7797) | amp (866) | p |
GA/tumor | 7.424 | 8.802 | <.0001 | 7.424 | 8.806 | <.0001 | 7.424 | 8.622 | <.0001 |
CDH1 alteration | 3.9% | 4.5% | 0.45 | 3.9% | 6.3% | 0.07 | 3.9% | 1.6% | 0.001 |
ERBB3 alteration | 5.8% | 8.3% | 0.02 | 5.8% | 11.1% | 0.001 | 5.8% | 6.1% | 0.65 |
FGFR3 alteration | 20.3% | 8.5% | <.0001 | 20.3% | 9.1% | <.0001 | 20.3% | 5.3% | <.0001 |
TP53 alteration | 58.3% | 58.6% | 0.86 | 58.3% | 51.8% | 0.06 | 58.3% | 79.4% | <.0001 |
APOBEC signature | 58.3% | 58.6% | 0.86 | 58.3% | 51.8% | 0.06 | 58.3% | 79.4% | <.0001 |
MSI-high | 0.8% | 0.5% | 0.63 | 0.8% | 3.6% | 0.002 | 0.8% | 0.0% | 0.009 |
Mean TMB | 9.14 | 17.02 | <.0001 | 9.14 | 16.34 | 0.002 | 9.14 | 11.79 | <.0001 |
PD-L1 high | 18.0% | 21.4% | 0.72 | 18.0% | 33.3% | 0.46 | 18.0% | 13.0% | 0.77 |
Conclusions
We noted important differences in co-occurrent-GA in ERBB2-altered (ECDmut, KDmut, amp) vs wt UBC, and higher mean TMB and higher APOBEC mut signature in the ERBB2-altered group. Results can help refine future clinical trial designs and help elucidate possible resistance mechanisms for ERBB2-altered UBC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Necchi: Financial Interests, Institutional, Research Grant: Merck, AstraZeneca, Ipsen, BMS, Gilead; Financial Interests, Personal, Steering Committee Member: Roche, Janssen, Bayer, Astellas, AstraZeneca, Merck, Clovis Oncology; Financial Interests, Coordinating PI: Incyte; Financial Interests, Local PI: Pfizer; Non-Financial Interests, Leadership Role: Global society of Rare Genitourinary Tumors (GSRGT). A. Kamat: Financial Interests, Personal, Advisory Board: Merck, Seagen, AstraZeneca, Janssen, CG Oncology, Astellas, Ferring; Financial Interests, Personal, Officer: International Bladder Cancer Group (IBCG); Financial Interests, Institutional, Advisory Board: CyPRIT; Non-Financial Interests, Leadership Role: IBCG, IBCN; Non-Financial Interests, Member of Board of Directors: AUA; Non-Financial Interests, Advisory Role: EAU. D.C. Pavlick, D.I. Lin: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine. N.A. Danziger: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine Inc.; Financial Interests, Personal, Stocks/Shares: F. Hoffman La-Roche LTd. R. Huang: Financial Interests, Personal, Full or part-time Employment: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche. J.S. Ross: Financial Interests, Personal, Full or part-time Employment, Medical Director: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche Holdings, Tango Therapeutics, Celsius Therapeutics. P. Grivas: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Bristol Myers Squibb, Asieris Pharmaceuticals, Merck KGaA, Seattle Genetics, Aadi Bioscience, Pfizer, Janssen, Boston Gene, Mirati Therapeutics, Exelixis, Genentech/Roche, Gilead Sciences, CG Oncology, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, ImmunityBio, Lucence Health, G1 Therapeutics, Fresenius Kabi, Guardant Health, PureTech, Regeneron Pharmaceuticals, Strata Oncology, Urogen, Silverback Therapeutics, Astellas Pharma; Financial Interests, Institutional, Local PI: Pfizer, Clovis Oncology, Bavarian Nordic, Gilead Sciences, Bristol Myers Squibb, Debiopharm Group, MSD, QED Therapeutics, Merck KGaA, GSK, Mirati Therapeutics, G1 Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
2380P - Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)
Presenter: Nicolas Sayegh
Session: Poster session 24
2381P - Perceived unmet needs and challenges faced by patients with advanced bladder cancer (aBC) and their caregivers: Results of a social media listening (SML) study conducted in 5 European countries
Presenter: Stephane Schuck
Session: Poster session 24
2382P - EBANO study: Clinical characteristics, treatment patterns and survival results in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) in northern Spain
Presenter: Ricardo Fernandez-Rodriguez
Session: Poster session 24
2383P - Stereotactic body radiotherapy (SBRT) of patients with oligometastatic urothelial cancer (UC): A single institution experience
Presenter: Faith Jawdat
Session: Poster session 24
2384P - Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study
Presenter: Eojin Kim
Session: Poster session 24
2385P - Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
Presenter: Chantal Stockem
Session: Poster session 24
2386P - Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): Results of a retrospective observational study in Germany
Presenter: Günter Niegisch
Session: Poster session 24
2387P - Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la/mUC): Treatment (tx) patterns and real-world (rw) outcomes in the US
Presenter: Kenneth Carson
Session: Poster session 24
2390P - Correlation between overall survival and bladder-intact event-free survival in cystectomy-ineligible/refusal muscle-invasive bladder cancer patients in Sweden
Presenter: Kelvin Kwok
Session: Poster session 24